(6R,8S)-3-(allyl-benzyloxycarbonyl-amino)-8-tert-butoxycarbonylmethyl-8-methyl-4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-6-carboxylic acid → tert-butyl 2-[(6R,8S)-8-methyl-4-oxo-6-[[4-(N-phenylmethoxycarbonylcarbamimidoyl)phenyl]methylcarbamoyl]-3-[phenylmethoxycarbonyl(prop-2-enyl)amino]-6,7-dihydropyrrolo[1,2-a]pyrimidin-8-yl]acetate
反応式
[CH2:1]([N:4]([C:27]([O:29][CH2:30][C:31]1[CH:36]=[CH:35][CH:34]=[CH:33][CH:32]=1)=[O:28])[C:5]1[C:10](=[O:11])[N:9]2[C@@H:12]([C:24](O)=[O:25])[CH2:13][C@:14]([CH2:16][C:17]([O:19][C:20]([CH3:23])([CH3:22])[CH3:21])=[O:18])([CH3:15])[C:8]2=[N:7][CH:6]=1)[CH:2]=[CH2:3].[CH2:37]([O:44][C:45](=[O:57])[NH:46][C:47]([C:49]1[CH:54]=[CH:53][C:52]([CH2:55][NH2:56])=[CH:51][CH:50]=1)=[NH:48])[C:38]1[CH:43]=[CH:42][CH:41]=[CH:40][CH:39]=1>>[C:20]([O:19][C:17](=[O:18])[CH2:16][C@@:14]1([CH3:15])[C:8]2=[N:7][CH:6]=[C:5]([N:4]([CH2:1][CH:2]=[CH2:3])[C:27]([O:29][CH2:30][C:31]3[CH:36]=[CH:35][CH:34]=[CH:33][CH:32]=3)=[O:28])[C:10](=[O:11])[N:9]2[C@@H:12]([C:24](=[O:25])[NH:56][CH2:55][C:52]2[CH:51]=[CH:50][C:49]([C:47]([NH:46][C:45]([O:44][CH2:37][C:38]3[CH:43]=[CH:42][CH:41]=[CH:40][CH:39]=3)=[O:57])=[NH:48])=[CH:54][CH:53]=2)[CH2:13]1)([CH3:21])([CH3:23])[CH3:22]参加物
3
反応物 2
生成物 1
実験手順
Following a procedure similar to that for the preparation of 18 g, intermediate 38c (268.9 mg, 0.54 mmol) was coupled with [(4-aminomethyl-phenyl)-imino-methyl]-carbamic acid benzyl ester (223.9 mg, 0.70 mmol) to provide 262.3 mg (64%) of intermediate 38d. MS (ESI) 763.5 (M+H+).
出典と根拠
- ORDレコード
- ord-c502c53106154f779abd910b4f76f1a5
- 出典データセット
- uspto-grants-2006_08
- 特許番号
- US07094783B2
関連ノート
読み込み中…